[Disclosure] Hanamicron(067310) Lists 28,000 New Shares Following Stock Option Exercise (May 17, 2024)

Fact Source: Financial Supervisory Service – Data Analysis, Retrieval and Transfer System (DART) / 2024-05-13

Disclosure Type: Additional Listing (Exercise of Stock Options)

💡 3-Second Summary Hanamicron is listing 28,000 new shares as employees exercise their previously granted stock options.

📊 1. [Key Details and Figures]

• Additional Shares: 28,000 common shares
• Exercise Price: 9,275 KRW per share
• Par Value: 500 KRW
• Total Outstanding Shares Post-Listing: 52,169,475 shares
• Listing Date: May 17, 2024

📈 2. [Expert Insight: Impact Analysis on Stock Price]

This additional listing is a standard procedure following the exercise of employee stock options.

• Dilution Effect: The 28,000 new shares represent approximately 0.05% of the total outstanding shares (52.17 million), resulting in a negligible dilution effect.
• Strategic Signal: The exercise of these options at 9,275 KRW suggests that employees perceive the current market price as holding value, serving as a subtle signal of confidence from internal stakeholders regarding the company’s outlook.
• Conclusion: This event is unlikely to cause any significant market volatility and should be viewed more as a demonstration of internal sentiment rather than a financial risk.

📝 Editor’s Comment (by K-STOCK Editor)

While the headline might suggest “supply pressure,” the scale of 28,000 shares is far too small to trigger any negative market impact. The real focus should be on the exercise price of 9,275 KRW. Stock options are a reward for those who have contributed to the company’s growth. Whether this exercise marks a long-term commitment or a realization of gains is for the market to decide, but it certainly underscores that internal players see value at these price levels.

📢 Disclaimer Source: This content is structured and written based on official data submitted to the Financial Supervisory Service’s DART system. Investment Risk Notice: This content is provided for informational and reference purposes only. It does not constitute financial advice or a recommendation to buy or sell any stock. All investment decisions and financial responsibilities rest solely with the investor. Inquiry: For compliance or copyright-related matters, please contact ksb220805@gmail.com